The United Laboratories (3933) Completes Phase II Clinical Trial for UBT251 Injection

Bulletin Express02-24

The United Laboratories International Holdings Limited (3933) announced the completion of its Phase II clinical trial for UBT251 Injection in participants with overweight or obesity. According to the announcement, the trial enrolled 205 patients with a baseline mean body weight of 92.20 kg and a baseline mean BMI of 33.10 kg/m². The study was a randomized, double-blind, parallel, placebo-controlled design, with patients assigned to either placebo or UBT251 Injection in various dose groups over 24 weeks.

Results showed that the maximum mean body weight reduction reached 19.70% (17.50 kg) in the UBT251 groups, compared to 2.00% (1.60 kg) in the placebo group. The announcement also noted significant improvements in secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids. The tolerability profile was generally favorable, with the most common adverse events being mild to moderate gastrointestinal reactions.

The company intends to advance UBT251 to Phase III clinical trials for overweight/obesity in China. UBT251 is a triple-target receptor agonist of GLP-1, GIP, and GCG, approved for clinical research in multiple indications including type 2 diabetes, overweight/obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis. Additionally, an exclusive license agreement for UBT251 was signed in March 2025 between United Biotechnology, a subsidiary of The United Laboratories, and Novo Nordisk A/S.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169113647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169113647","market":"us","top_or_hot":-1,"title":"The United Laboratories (3933) Completes Phase II Clinical Trial for UBT251 Injection","media":"Bulletin Express","content":"<p>The United Laboratories International Holdings Limited (3933) announced the completion of its Phase II clinical trial for UBT251 Injection in participants with overweight or obesity. According to the announcement, the trial enrolled 205 patients with a baseline mean body weight of 92.20 kg and a baseline mean BMI of 33.10 kg/m². The study was a randomized, double-blind, parallel, placebo-controlled design, with patients assigned to either placebo or UBT251 Injection in various dose groups over 24 weeks.</p>\n<p>Results showed that the maximum mean body weight reduction reached 19.70% (17.50 kg) in the UBT251 groups, compared to 2.00% (1.60 kg) in the placebo group. The announcement also noted significant improvements in secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids. The tolerability profile was generally favorable, with the most common adverse events being mild to moderate gastrointestinal reactions.</p>\n<p>The company intends to advance UBT251 to Phase III clinical trials for overweight/obesity in China. UBT251 is a triple-target receptor agonist of GLP-1, GIP, and GCG, approved for clinical research in multiple indications including type 2 diabetes, overweight/obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis. Additionally, an exclusive license agreement for UBT251 was signed in March 2025 between United Biotechnology, a subsidiary of The United Laboratories, and Novo Nordisk A/S.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The United Laboratories (3933) Completes Phase II Clinical Trial for UBT251 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe United Laboratories (3933) Completes Phase II Clinical Trial for UBT251 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-24 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The United Laboratories International Holdings Limited (3933) announced the completion of its Phase II clinical trial for UBT251 Injection in participants with overweight or obesity. According to the announcement, the trial enrolled 205 patients with a baseline mean body weight of 92.20 kg and a baseline mean BMI of 33.10 kg/m². The study was a randomized, double-blind, parallel, placebo-controlled design, with patients assigned to either placebo or UBT251 Injection in various dose groups over 24 weeks.</p>\n<p>Results showed that the maximum mean body weight reduction reached 19.70% (17.50 kg) in the UBT251 groups, compared to 2.00% (1.60 kg) in the placebo group. The announcement also noted significant improvements in secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids. The tolerability profile was generally favorable, with the most common adverse events being mild to moderate gastrointestinal reactions.</p>\n<p>The company intends to advance UBT251 to Phase III clinical trials for overweight/obesity in China. UBT251 is a triple-target receptor agonist of GLP-1, GIP, and GCG, approved for clinical research in multiple indications including type 2 diabetes, overweight/obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis. Additionally, an exclusive license agreement for UBT251 was signed in March 2025 between United Biotechnology, a subsidiary of The United Laboratories, and Novo Nordisk A/S.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1169113647","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169113647","pubTimestamp":1771923850,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The United Laboratories International Holdings Limited (3933) announced the completion of its Phase II clinical trial for UBT251 Injection in participants with overweight or obesity. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药（3933）完成UBT251注射液II期临床试验","themeId":"f1cb9c263e4906c971f3030dfa725fa8","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"The United Laboratories International Holdings Limited (3933) announced the completion of its Phase II clinical trial for UBT251 Injection in participants with overweight or obesity. According to the announcement, the trial enrolled 205 patients with a baseline mean body weight of 92.20 kg and a baseline mean BMI of 33.10 kg/m². The study was a randomized, double-blind, parallel, placebo-controlled design, with patients assigned to either placebo or UBT251 Injection in various dose groups over 24 weeks.\nResults showed that the maximum mean body weight reduction reached 19.70% (17.50 kg) in the UBT251 groups, compared to 2.00% (1.60 kg) in the placebo group. The announcement also noted significant improvements in secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids. The tolerability profile was generally favorable, with the most common adverse events being mild to moderate gastrointestinal reactions.\nThe company intends to advance UBT251 to Phase III clinical trials for overweight/obesity in China. UBT251 is a triple-target receptor agonist of GLP-1, GIP, and GCG, approved for clinical research in multiple indications including type 2 diabetes, overweight/obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis. Additionally, an exclusive license agreement for UBT251 was signed in March 2025 between United Biotechnology, a subsidiary of The United Laboratories, and Novo Nordisk A/S.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169113647","isCrawlerRequest":true}